Assessing the Nationwide Impact of a Registry-Based Randomized Clinical Trial on Cardiovascular Practice.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationAssessing the Nationwide Impact of a Registry-Based Randomized Clinical Trial on Cardiovascular Practice. 2019, 12(3):e007381 Circ Cardiovasc Interv
ÚtdrátturBACKGROUND: Registry-based randomized clinical trials have emerged as useful tools to provide evidence on the comparative efficacy and safety of different therapeutic strategies. However, it remains unknown whether the results of registry-based randomized clinical trials have a sizable impact on daily clinical practice. We sought, therefore, to describe the temporal trends in thrombus aspiration (TA) use in Sweden before, during, and after dissemination of the TASTE trial (Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia) results. METHODS AND RESULTS: From January 1, 2006, to December 31, 2017, we included all consecutive patients with ST-segment-elevation myocardial infarction undergoing percutaneous revascularization in Sweden. All patients were registered in the Swedish Coronary Angiography and Angioplasty Registry. A total of 55 809 ST-segment-elevation myocardial infarction patients were included. TA use in Sweden substantially decreased after dissemination of TASTE results (from 39.8% to 11.8% during and after TASTE, respectively). Substantial variability in TA use across treating centers was observed before TASTE (TA use ranging from 0% to 70%), but after TASTE both the interhospital variability and the frequency of TA use were markedly reduced. A constant shift in medical practice was seen about 4 months after dissemination of the TASTE trial results. Time trends for all-cause mortality and definite stent thrombosis at 30 days were not associated with variations in TA use ( P values >0.05 using the Granger test). CONCLUSIONS: In Sweden, the results of the TASTE trial were impactful in daily clinical practice and led to a relevant decrease in TA use in ST-segment-elevation myocardial infarction patients undergoing percutaneous revascularization.
Lu00FDsingTo access publisher's full text version of this article click on the hyperlink below
- Impact of Thrombus Aspiration on Mortality, Stent Thrombosis, and Stroke in Patients With ST-Segment-Elevation Myocardial Infarction: A Report From the Swedish Coronary Angiography and Angioplasty Registry.
- Authors: Angerås O, Haraldsson I, Redfors B, Fröbert O, Petursson P, Albertsson P, Ioanes D, Odenstedt J, Olsson H, Witt N, Rück A, Millgård J, Nilsson J, Persson J, Söderbom M, Wedel H, Erlinge D, James S, Råmunddal T, Omerovic E
- Issue date: 2018 Jan 9
- Meta-analysis of randomized controlled trials comparing percutaneous coronary intervention with aspiration thrombectomy Vs. Conventional percutaneous coronary intervention during ST-segment elevation myocardial infarction.
- Authors: Dominguez AC, Bittl JA, El-Hayek G, Contreras E, Tamis-Holland JE
- Issue date: 2016 Jun
- Outcomes From Selective Use of Thrombectomy in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: An Analysis of the British Cardiovascular Intervention Society/National Institute for Cardiovascular Outcomes Research (BCIS-NICOR) Registry, 2006-2013.
- Authors: Sirker A, Mamas M, Kwok CS, Kontopantelis E, Ludman P, Hildick-Smith D, British Cardiovascular Intervention Society (BCIS).
- Issue date: 2016 Jan 25
- Thrombus Aspiration in ST-Segment-Elevation Myocardial Infarction: An Individual Patient Meta-Analysis: Thrombectomy Trialists Collaboration.
- Authors: Jolly SS, James S, Džavík V, Cairns JA, Mahmoud KD, Zijlstra F, Yusuf S, Olivecrona GK, Renlund H, Gao P, Lagerqvist B, Alazzoni A, Kedev S, Stankovic G, Meeks B, Frøbert O
- Issue date: 2017 Jan 10
- Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
- Authors: Grimfjärd P, Lagerqvist B, Erlinge D, Varenhorst C, James S
- Issue date: 2019 Jul 1